Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Part D/Commercial Firewalls Aid Negotiations On Donut Hole Discount Offsets

Executive Summary

Manufacturers often place firewalls between drug price negotiations for an insurer's commercial plans and Medicare Part D plans to avoid running afoul of federal anti-kickback statutes. This may have another benefit: providing latitude for Part D pricing that offsets the mandatory 50% discounts manufacturers will give on drugs used by Medicare patients in the donut hole.

You may also be interested in...



Part D Premiums Will Increase If Manufacturers Offset Donut Hole Drug Discounts With Lower Rebates, Humana Warns

Medicare Part D beneficiary premiums will increase if drug firms try to offset new 50 percent discounts on branded drugs provided to beneficiaries in the coverage gap by reducing or eliminating the rebates paid to plans, Humana VP-Pharmacy and Clinical Integration William Fleming warned at a June 1 CMS workshop

GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds

New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.

Deal Watch: Sanofi, Boehringer Swap Side Businesses

Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.

Topics

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel